NCT00003325
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
PHASE3
COMPLETED
NCT00003325
INTERVENTIONAL
Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva
RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva.
PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.
DISEASE CHARACTERISTICS:
* Histologically confirmed invasive squamous cell carcinoma of the vulva that is greater than 1 mm in thickness as measured from the nearest rete peg
* Tumor size must be 2-6 cm
* No recurrent disease
* Prior excision of the primary disease or a history of carcinoma in situ of the vulva allowed
* No tumor extending into the urethra, anus, vagina, rectum, or bladder
* No grossly suspicious or inflamed groin nodes on physical exam
* No grossly infected primary tumors
PATIENT CHARACTERISTICS:
Age:
* Any age
Performance status:
* GOG 0-3
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No other invasive malignancy within the past 5 years except non-melanomatous skin cancer
* No known hypersensitivity to phenylethane compounds
PRIOR CONCURRENT THERAPY:
* No prior cancer therapy that contraindicates therapy in this study
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
* No prior groin dissection
Vulvar Cancer
- TREATMENT
-
- Type: PROCEDURE
- Name: Sentinel lymph node mapping
- Description: Sentinel lymph node mapping
- Arm Group Labels: Sentinenal lymph node mapping
- Gynecologic Oncology Group